Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Ja Min Byun, Meletios Dimopoulos, Eeman Shaikh, Karen Gogat-Marchant, Nina N. Green, Domenico Cieri, Hang Quach

Blood (2025) 146 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2025-5845

Published: 2025

Journal Articles

A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial

Ja Min Byun, Ludek Pour, Jiri Minarik, H. Miles Prince, Elham Askari, Su-Peng Yeh, Albert Oriol, Satoshi Ito, Darrel White, Eeman Shaikh, Nina N. Green, Eric Leip, Andrea Viqueira, Hang Quach

Blood (2025) 146 (Supplement 1): 2253.

https://doi.org/10.1182/blood-2025-2253

Published: 2025